{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:33:14Z","timestamp":1793403194477,"version":"4.5.0"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2019.00943","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T05:05:27Z","timestamp":1579583127000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":156,"title":["Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials"],"prefix":"10.3389","volume":"10","author":[{"given":"Juan Jos\u00e9","family":"Fuentes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francina","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Elices","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mag\u00ed","family":"Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Torrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hlca.19430260326","article-title":"Partialsynthese von Alkaloiden vom Typus des Ergobasins. (6. Mitteilung \u00fcber Mutterkornalkaloide)","volume":"26","author":"Stoll","year":"1943","journal-title":"Helv Chim Acta"},{"key":"B2","article-title":"LSD: My problem child and insights\/outlooks","volume-title":"J. Ott, Trans","author":"Hofmann","year":"2013"},{"key":"B3","article-title":"L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug","volume":"11","author":"Busch","year":"1950","journal-title":"Dis Nerv Syst"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","article-title":"A review of the clinical effects of psychotomimetic agents","volume":"66","author":"Osmond","year":"1957","journal-title":"Ann N Y Acad Sci"},{"key":"B5","volume-title":"Acid dreams: the complete social history of LSD: the CIA, the sixties, and beyond","author":"Lee","year":"1992"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/scientificamerican1210-76","article-title":"Hallucinogens as medicine","volume":"303","author":"Griffths","year":"2010","journal-title":"Sci Am"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.345.6192.18","article-title":"High hopes","volume":"345","author":"Kupferschmidt","year":"2014","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.186.6.457","article-title":"Can psychedelics have a role in psychiatry once again","volume":"186","author":"Sessa","year":"2005","journal-title":"Br J Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.615318","article-title":"Clinical toxicology of newer recreational drugs","volume":"49","author":"Hill","year":"2011","journal-title":"Clin Toxicol"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1007\/978-88-470-5322-9_27","article-title":"Addiction to hallucinogens, dissociatives, designer drugs and \u201cLegal Highs","volume-title":"Textbook of Addiction Treatment: International Perspectives","author":"Farr\u00e9","year":"2015"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1192\/bjp.bp.111.103309","article-title":"Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin","volume":"200","author":"Carhart-Harris","year":"2012","journal-title":"Br J Psychiatry"},{"key":"B14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1080\/02791072.1979.10472098","article-title":"Entheogens","volume":"11","author":"Ruck","year":"1979","journal-title":"J Psychedelic Drugs"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1016\/0024-3205(84)90436-3","article-title":"Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents","volume":"35","author":"Glennon","year":"1984","journal-title":"Life Sci"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1016\/0014-2999(83)90464-8","article-title":"Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists","volume":"91","author":"Glennon","year":"1983","journal-title":"Eur J Pharmacol"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.3007-12.2013","article-title":"Activation of serotonin 2A receptors underlies the psilocybin-induced effects on oscillations, N170 visual-evoked potentials, and visual hallucinations","volume":"33","author":"Kometer","year":"2013","journal-title":"J Neurosci"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2012.04.005","article-title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors","volume":"72","author":"Kometer","year":"2012","journal-title":"Biol Psychiatry"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2016.03.012","article-title":"Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans","volume":"26","author":"Valle","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.23-26-08836.2003","article-title":"Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex","volume":"23","author":"Gonz\u00e1lez-Maeso","year":"2003","journal-title":"J Neurosci"},{"key":"B24","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic drugs in biomedicine","volume":"38","author":"Kyzar","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"B25","article-title":"[Club drugs: old medicines as new party drugs]","volume":"123","author":"Abanades","year":"2004","journal-title":"Med Clin"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyz029","article-title":"Motives and side-effects of microdosing with psychedelics among users","volume":"22","author":"Hutten","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"B28","article-title":"A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects","volume":"7","author":"Liester","year":"2014","journal-title":"Curr Drug Abuse Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J Psychopharmacoly."},{"key":"B30","volume-title":"Psychedelic drugs reconsidered","author":"Grinspoon","year":"1997"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.3109\/00048677009159331","article-title":"The uses and abuses of L.S.D. and other hallucinogenic drugs","volume":"4","author":"Barnes","year":"1970","journal-title":"Aust N Z J Psychiatry"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacol"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2007.07.018","article-title":"The behavioral pharmacology of hallucinogens","volume":"75","author":"Fantegrossi","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic hallucinogens in the treatment of addictions","volume":"64","author":"Bogenschutz","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.3109\/00952999309001618","article-title":"Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically","volume":"19","author":"Gable","year":"1993","journal-title":"Am J Drug Alcohol Abuse"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1097\/00005053-198410000-00001","article-title":"Adverse reactions to psychedelic drugs. A review of the literature","volume":"172","author":"Strassman","year":"1984","journal-title":"J Nerv Ment Dis"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1177\/0269881113477744","article-title":"Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users","volume":"27","author":"Morgan","year":"2013","journal-title":"J Psychopharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115581980","article-title":"European rating of drug harms","volume":"29","author":"van Amsterdam","year":"2015","journal-title":"J Psychopharmacol"},{"key":"B41","article-title":"Harm potential of magic mushroom use: a review","volume":"59","author":"van Amsterdam","year":"2011","journal-title":"Regul Toxicol Pharmacol"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2013.03.007","article-title":"Physical harm due to chronic substance use","volume":"66","author":"van Amsterdam","year":"2013","journal-title":"Regul Toxicol Pharmacol"},{"key":"B43","doi-asserted-by":"crossref","first-page":"h2902","DOI":"10.1136\/bmj.h2902","article-title":"Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential","volume":"350","author":"Rucker","year":"2015","journal-title":"BMJ"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1176\/ajp.123.7.884","article-title":"Suicide During an LSD Reaction","volume":"123","author":"Keeler","year":"1967","journal-title":"Am J Psychiatry"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1093\/jat\/9.4.183","article-title":"A mescaline associated fatality","volume":"9","author":"Reynolds","year":"1985","journal-title":"J Anal Toxicol"},{"key":"B46","doi-asserted-by":"crossref","first-page":"e016025","DOI":"10.1136\/bmjopen-2017-016025","article-title":"Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting","volume":"7","author":"Argento","year":"2017","journal-title":"BMJ Open"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1177\/0269881115598338","article-title":"Psilocybin, psychological distress, and suicidality","volume":"29","author":"Hendricks","year":"2015","journal-title":"J Psychopharmacol"},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.1177\/0269881114565653","article-title":"Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population","volume":"29","author":"Hendricks","year":"2015","journal-title":"J Psychopharmacol"},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.1177\/0269881114568039","article-title":"Psychedelics not linked to mental health problems or suicidal behavior: a population study","volume":"29","author":"Johansen","year":"2015","journal-title":"J Psychopharmacol"},{"key":"B50","doi-asserted-by":"crossref","first-page":"e63972","DOI":"10.1371\/journal.pone.0063972","article-title":"Psychedelics and mental health: a population study","volume":"8","author":"Krebs","year":"2013","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1177\/2045125316640440","article-title":"Lysergic acid diethylamide: a drug of \u2018use'","volume":"6","author":"Das","year":"2016","journal-title":"Ther Adv Psychopharmacol"},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.1176\/appi.psychotherapy.1966.20.3.415","article-title":"LSD in psychotherapy and alcoholism","volume":"20","author":"Abramson","year":"1966","journal-title":"Am J Psychother"},{"key":"B53","volume-title":"The Human Encounter With Death","author":"Grof","year":"1978"},{"key":"B54","doi-asserted-by":"crossref","DOI":"10.1159\/000467984","article-title":"LSD-assisted psychotherapy in patients with terminal cancer","volume":"8","author":"Grof","year":"1973","journal-title":"Int Pharmacopsychiatry."},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1213\/00000539-196405000-00013","article-title":"Study of lysergic acid diethylamide as an analgesic agent","volume":"43","author":"Kast","year":"1964","journal-title":"Anesth Analg."},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.1080\/02791072.1985.10524332","article-title":"LSD in the supportive care of the terminally ill cancer patient","volume":"17","author":"Kurland","year":"1985","journal-title":"J Psychoactive Drugs"},{"key":"B57","article-title":"LSD-assisted psychotherapy with terminal cancer patients","volume":"9","author":"Pahnke","year":"1969","journal-title":"Curr Psychiatr Ther"},{"key":"B58","doi-asserted-by":"crossref","DOI":"10.1007\/BF01564376","article-title":"Resistance to lysergic acid in schizophrenic patients","volume":"30","author":"Cline","year":"1956","journal-title":"Psychiatr Quarterly"},{"key":"B59","doi-asserted-by":"crossref","DOI":"10.15288\/qjsa.1970.31.932","article-title":"Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation","volume":"31","author":"Tomsovic","year":"1970","journal-title":"Q J Stud Alcohol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1177\/070674376300800305","article-title":"Treatment of chronic alcoholism with lysergic acid diethylamide","volume":"8","author":"Jensen","year":"1963","journal-title":"Can Psychiatr Assoc J"},{"key":"B61","doi-asserted-by":"crossref","DOI":"10.15288\/qjsa.1958.19.406","article-title":"A new adjunct to the treatment of alcoholism: the hallucinogenic drugs","volume":"19","author":"Smith","year":"1958","journal-title":"Q J Stud Alcohol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1001\/jama.212.11.1856","article-title":"The experimental use of psychedelic (LSD) psychotherapy","volume":"212","author":"Pahnke","year":"1970","journal-title":"JAMA"},{"key":"B63","doi-asserted-by":"crossref","DOI":"10.1177\/0269881114568040","article-title":"Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences","volume":"29","author":"Maji\u0107","year":"2015","journal-title":"J Psychopharmacol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2307\/2023306","article-title":"The teachings of the mystics: being selections from the great mystics and mystical writings of the world","volume":"59","author":"Hick","year":"1962","journal-title":"J Philos."},{"key":"B65","volume-title":"LSD-assisted psychotherapy in the treatment of severe chronic neurosis","author":"Savage","year":""},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"B67","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch8","article-title":"Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.15288\/qjsa.1966.27.469","article-title":"A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior","volume":"27","author":"Smart","year":"1966","journal-title":"Q J Stud Alcohol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.125.10.1352","article-title":"A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics","volume":"125","author":"Hollister","year":"1969","journal-title":"Am J Psychiatry"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.126.1.59","article-title":"A clinical study of LSD treatment in alcoholism","volume":"126","author":"Ludwig","year":"1969","journal-title":"Am J Psychiatry"},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.1176\/ajp.126.4.481","article-title":"LSD in the treatment of alcoholism","volume":"126","author":"Johnson","year":"1969","journal-title":"Am J Psychiatry"},{"key":"B72","doi-asserted-by":"crossref","DOI":"10.1097\/00005053-197002000-00003","article-title":"Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study","volume":"150","author":"Bowen","year":"1970","journal-title":"J Nerv Ment Dis"},{"key":"B73","doi-asserted-by":"crossref","DOI":"10.1192\/bjp.116.533.443","article-title":"A controlled study of LSD treatment in alcoholism and neurosis","volume":"116","author":"Denson","year":"1970","journal-title":"Br J Psychiatry"},{"key":"B74","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential Psychedelic (LSD) Therapy for the Narcotic Addict","volume":"28","author":"Savage","year":"1973","journal-title":"Arch Gen Psychiatry"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J Nerv Mental Dis"},{"key":"B76","doi-asserted-by":"crossref","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J Psychopharmacol"},{"key":"B77","doi-asserted-by":"crossref","DOI":"10.1037\/h0088594","article-title":"Personality change associated with psychedelic (LSD) therapy: a preliminary report","volume":"1","author":"Mogar","year":"1964","journal-title":"Psychother.: Theory Res Practice."},{"key":"B78","doi-asserted-by":"crossref","DOI":"10.1097\/00005053-196706000-00004","article-title":"Therapeutic effects of LSD: a follow-up study","volume":"144","author":"Shagass","year":"1967","journal-title":"J Nerv Ment Dis"},{"key":"B79","doi-asserted-by":"crossref","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J Psychopharmacol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4733-3","article-title":"Long-lasting subjective effects of LSD in normal subjects","volume":"235","author":"Schmid","year":"2018","journal-title":"Psychopharmacol"},{"key":"B81","doi-asserted-by":"crossref","DOI":"10.15288\/qjsa.1962.23.315","article-title":"A treatment program for alcoholics in a mental hospital","volume":"23","author":"Jensen","year":"1962","journal-title":"Q J Stud Alcohol"},{"key":"B82","doi-asserted-by":"crossref","DOI":"10.1111\/j.1749-6632.1981.tb12805.x","article-title":"Therapeutic uses of the drugs of abuse","volume":"362","author":"Ungerleider","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"B83","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"key":"B84","doi-asserted-by":"crossref","DOI":"10.2174\/138161210791516431","article-title":"Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment","volume":"16","author":"Krampe","year":"2010","journal-title":"Curr Pharm Des"},{"key":"B85","first-page":"CD004332","article-title":"Acamprosate for alcohol dependence","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B86","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B87","doi-asserted-by":"crossref","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J Psychopharmacol"},{"key":"B88","doi-asserted-by":"crossref","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B89","doi-asserted-by":"crossref","first-page":"205032451668332","DOI":"10.1177\/2050324516683325","article-title":"Constructing drug effects: a history of set and setting","volume":"3","author":"Hartogsohn","year":"2017","journal-title":"Drug Science Policy Law"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-196312000-00007","article-title":"Reactions to psilocybin administered in a supportive environment","volume":"137","author":"Leary","year":"1963","journal-title":"J Nerv Ment Dis"},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.15288\/qjsa.1967.28.140","article-title":"Treatment of alcoholism with lysergide. Comment on the article by Smart et al., with special reference to issues of responsibility in research reporting","volume":"28","author":"MacLean","year":"1967","journal-title":"Q J Stud Alcohol"},{"key":"B92","article-title":"Lysergic acid diethylamide in psychotherapy","volume":"1","author":"Whitaker","year":"1964","journal-title":"Med J Aust"},{"key":"B93","doi-asserted-by":"crossref","DOI":"10.1093\/jhmas\/jrs050","article-title":"Efficacy and enlightenment: LSD psychotherapy and the drug amendments of 1962","volume":"69","author":"Oram","year":"2014","journal-title":"J Hist Med Allied Sci"},{"key":"B94","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacol"},{"key":"B95","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose?effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacol"},{"key":"B96","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fnhum.2016.00269","article-title":"Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)","volume":"10","author":"Nour","year":"2016","journal-title":"Front Hum Neurosci"},{"key":"B97","doi-asserted-by":"crossref","first-page":"e30800","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PloS One"},{"key":"B98","doi-asserted-by":"crossref","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J Psychopharmacol"},{"key":"B99","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3389\/fphar.2018.00897","article-title":"Predicting responses to psychedelics: a prospective study","volume":"9","author":"Haijen","year":"2018","journal-title":"Front Pharmacol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front Pharmacol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Curr Drug Abuse Rev"},{"key":"B102","doi-asserted-by":"crossref","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B103","article-title":"The hidden therapist: evidence for a central role of music in psychedelic therapy","volume":"235","author":"Kaelen","year":"2018","journal-title":"Psychopharmacol"},{"key":"B104","doi-asserted-by":"crossref","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J Psychopharmacol"},{"key":"B105","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2017_474","article-title":"Classic hallucinogens and mystical experiences: phenomenology and neural correlates","volume":"36","author":"Barrett","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"key":"B106","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1518377113","article-title":"Neural correlates of the LSD experience revealed by multimodal neuroimaging","volume":"113","author":"Carhart-Harris","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B107","doi-asserted-by":"crossref","DOI":"10.1177\/0269881116628430","article-title":"Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide","volume":"30","author":"Speth","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B108","doi-asserted-by":"crossref","first-page":"46421","DOI":"10.1038\/srep46421","article-title":"Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin","volume":"7","author":"Schartner","year":"2017","journal-title":"Sci Rep"},{"key":"B109","doi-asserted-by":"crossref","DOI":"10.1016\/j.cub.2016.02.010","article-title":"Increased global functional connectivity correlates with LSD-induced ego dissolution","volume":"26","author":"Tagliazucchi","year":"2016","journal-title":"Curr Biol"},{"key":"B110","doi-asserted-by":"crossref","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B111","doi-asserted-by":"crossref","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"key":"B112","doi-asserted-by":"crossref","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2A R agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"B114","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000219761.05466.43","article-title":"Response of cluster headache to psilocybin and LSD","volume":"66","author":"Sewell","year":"2006","journal-title":"Neurology"},{"key":"B116","unstructured":"The altering state of psychedelics research | CIIS DenenmarkL 2015"},{"key":"B117","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T01:42:18Z","timestamp":1614044538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":117,"alternative-id":["10.3389\/fpsyt.2019.00943"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2019.00943","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,21]]},"article-number":"943"}}